Figure 4

Expression of UHRF1 correlated with the stage, grade, and the risk after TURBT. (A) Expression of UHRF1 in 21 normal bladders, 71 superficial bladder tumours (T-category is pTa and pT1), and 41 invasive bladder tumours (T-category is pT2, pT3, and pT4) detected by TaqMan qRT–PCR. Expression levels of UHRF1 in superficial bladder tumours and in invasive tumours were significantly higher compared with those in normal bladders by Mann–Whitney’s U-test (P=0.0063 and 0.0034, respectively). Although its expression in superficial tumours and invasive tumours did not differ (P=0.2442, Mann–Whitney’s U-test), it differed among the three different groups (P=0.0058, Kruskal–Wallis’ test). β2-microglobulin was used for normalisation. (B) Expression of UHRF1 differed among four groups with the different grade (P=0.0156, Kruskal–Wallis’ test) detected by TaqMan qRT–PCR. Expression of UHRF1 in grades II and III tumour was higher than that in the normal bladders (P=0.0033 and 0.0041). β2-microglobulin was used for normalisation. (C) Significant high expression of UHRF1 in the high-risk group after TURBT (n=23) was observed compared with that in the low-risk group (n=7) by Mann–Whitney’s U-test (P=0.0350). Asterisk indicates statistically significant P-values. β2-microglobulin was used for normalisation.